To Investigate the Efficacy and Mechanism of ZBP Powder Product in the Treatment of Osteopenia in Patients With Pain.

Last updated: April 27, 2020
Sponsor: Taipei Medical University WanFang Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Osteopenia

Treatment

N/A

Clinical Study ID

NCT03245710
N201602096
  • Ages > 50
  • All Genders

Study Summary

This study investigates the efficacy and mechanism of traditional Chinese medicine formula power product in the treatment of osteopenia in patients with pain. Half of participants will receive Chinese medicine formula power product, while the other half will receive a placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. aged 50 years or older.

  2. VAS score≧4.0 in a week.

  3. bone mineral density (BMD) of all participants was -2.5 or below.

Exclusion

Exclusion Criteria:

  1. diabetes.

  2. thyroidism function disorder.

  3. parathyroidism function disorder.

  4. liver or kidney function disorder.

  5. ovariectomy

  6. rheumatoid arthritis.

  7. bone cancer.

  8. ever used hormone agent within 6 months before assignment to treatment.

  9. ever used steroids more than 3 months before assignment to treatment.

  10. ever used analgesics, excepted acetaminophen, more than 1 week before assignment totreatment.

Study Design

Total Participants: 80
Study Start date:
February 08, 2017
Estimated Completion Date:
March 07, 2021

Study Description

Osteoporosis is a major public health problem, resulting in potentially pain and increasing risk of fracture. Treatment of osteoporosis consists of pharmacotherapy, lifestyle measures, dietary changes, mineral supplementation. Traditional Chinese medicine is a major component of health care in Taiwan and provides one treatment alternative for osteoporosis.

Investigators investigate the efficacy and mechanism of traditional Chinese medicine formula powder product in the treatment of osteopenia patients with pain.This trial is a 12 weeks' randomized, placebo-controlled study. The study was approved by the Wan Fang hospital, and signed informed consent was obtained from each participant. 80 Osteopenia participants with pain were enrolled in this study. There were 80 participants aged 50 years or older included. Before random assignment to treatment, participants were at least moderate pain during 2 weeks as identified by visual analogue scale (VAS) for more than 4. Bone mineral density (BMD) of all participants was -2.5 or below without diabetes, hyperthyroidism, hypoparathyroidism, liver or kidney function disorder, ovariectomy, rheumatoid arthritis, bone cancer, ever used hormone agent within 6 months before assignment to treatment, ever used steroids more than 3 week before assignment to treatment, Primary outcome measures were the change of VAS scale, Oswestry Disability Index and WHOQOL-BREF Taiwan at week 1 and 12. Secondary outcome was the genetic loci associated with a susceptibility to osteoprosis treated by traditional Chinese medicine formula powder product.

Result : To provide evidence of the efficacy and mechanisms of ZBP powder product in the treatment of osteoporosis patients with pain.

Connect with a study center

  • WanFangH

    Taipei, 116
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.